PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Javitt, A.* ; Shmueli, M.D.* ; Kramer, M.P.* ; Kolodziejczyk, A.A.* ; Cohen, I.J.* ; Radomir, L.* ; Sheban, D.* ; Kamer, I.* ; Litchfield, K.* ; Bab-Dinitz, E.* ; Zadok, O.* ; Neiens, V. ; Ulman, A.* ; Wolf-Levy, H.* ; Eisenberg-Lerner, A.* ; Kacen, A.* ; Alon, M.* ; Rêgo, A.T.* ; Stacher-Priehse, E.* ; Lindner, M.* ; Koch, I.* ; Bar, J.* ; Swanton, C.* ; Samuels, Y.* ; Levin, Y.* ; da Fonseca, P.C.A.* ; Elinav, E.* ; Friedman, N.* ; Meiners, S. ; Merbl, Y.*

The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.

Nat. Cancer 4, 629-647 (2023)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Immunotherapy revolutionized treatment options in cancer, yet the mechanisms underlying resistance in many patients remain poorly understood. Cellular proteasomes have been implicated in modulating antitumor immunity by regulating antigen processing, antigen presentation, inflammatory signaling and immune cell activation. However, whether and how proteasome complex heterogeneity may affect tumor progression and the response to immunotherapy has not been systematically examined. Here, we show that proteasome complex composition varies substantially across cancers and impacts tumor-immune interactions and the tumor microenvironment. Through profiling of the degradation landscape of patient-derived non-small-cell lung carcinoma samples, we find that the proteasome regulator PSME4 is upregulated in tumors, alters proteasome activity, attenuates presented antigenic diversity and associates with lack of response to immunotherapy. Collectively, our approach affords a paradigm by which proteasome composition heterogeneity and function should be examined across cancer types and targeted in the context of precision oncology.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
22.700
0.000
3
4
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Mhc Class-i; 20 S-proteasomes; Enrichment Analysis; Gamma-interferon; Ctla-4 Blockade; Reveals; Cancer; Pa28; Expression; Tumors
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2662-1347
e-ISSN 2662-1347
Zeitschrift Nature Cancer
Quellenangaben Band: 4, Heft: 5, Seiten: 629-647 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Heidelberger Platz 3, Berlin, 14197, Germany
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 80000 - German Center for Lung Research
30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501800-816
G-501600-004
Förderungen European Research Council (ERC)

Marie Sklodowska-Curie Individual Fellowship
Abisch-Frenkel Foundation for the Promotion of Life Sciences
Melanoma Research Alliance award
Cancer Research Institute/Israel Cancer Research Fund CLIP Grant
Israel Science Foundation
I-CORE Program of the Planning and Budgeting Committee
European Union
DOI 10.1038/s43018-023-00557-4
WOS ID 000992443400001
Scopus ID 85160095008
PubMed ID 37217651
Erfassungsdatum 2023-10-06
[➜Korrektur melden]